Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Third quarter total revenue of $55.3 million, which includes TAVALISSE® net product sales of$26.3 million, REZLIDHIA® net product sales of $5.5 million and GAVRETO® net product sales of$7.1 million Entered into an agreement with Kissei to develop and commercialize REZLIDHIA in all potential indications in Japan, the Republic of Korea and Taiwan, recording an upfront cash payment of $10.0 million during the third quarter Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibit ...